12/3
08:06 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $25.00 price target on the stock.
Low
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $25.00 price target on the stock.
12/3
07:00 am
nrxp
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation
Medium
Report
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation
12/2
07:07 pm
nrxp
NRx Pharmaceuticals (NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date [Yahoo! Finance]
Medium
Report
NRx Pharmaceuticals (NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date [Yahoo! Finance]
12/2
11:27 am
nrxp
NRx Pharmaceuticals, Inc. (NRXP) Discusses Regulatory Update and Development Pipeline Expansion for Preservative-Free Ketamine Formulation Transcript [Seeking Alpha]
Medium
Report
NRx Pharmaceuticals, Inc. (NRXP) Discusses Regulatory Update and Development Pipeline Expansion for Preservative-Free Ketamine Formulation Transcript [Seeking Alpha]
12/2
10:40 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
12/2
08:30 am
nrxp
NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine
High
Report
NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine
12/2
07:30 am
nrxp
NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call
High
Report
NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call
12/1
08:52 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference [Yahoo! Finance]
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference [Yahoo! Finance]
12/1
08:03 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference
Low
Report
NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference
11/23
02:11 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) was upgraded by analysts at
Wall Stree
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) was upgraded by analysts at
Wall Stree
11/17
04:33 pm
nrxp
NRX Pharmaceuticals Inc (NRXP) Q3 2025 Earnings Call Highlights: Strategic Clinic Expansion and ... [Yahoo! Finance]
Medium
Report
NRX Pharmaceuticals Inc (NRXP) Q3 2025 Earnings Call Highlights: Strategic Clinic Expansion and ... [Yahoo! Finance]
11/17
01:19 pm
nrxp
NRx Pharmaceuticals, Inc. (NRXP) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
NRx Pharmaceuticals, Inc. (NRXP) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/17
08:43 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
11/17
08:03 am
nrxp
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update
High
Report
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/12
08:31 am
nrxp
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025
Medium
Report
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025
11/10
03:40 pm
nrxp
NRx Pharmaceuticals (NRXP) Launches HOPE Therapeutics' One-Day TMS Protocol for Treatment-Resistant Depression in Florida [Yahoo! Finance]
Low
Report
NRx Pharmaceuticals (NRXP) Launches HOPE Therapeutics' One-Day TMS Protocol for Treatment-Resistant Depression in Florida [Yahoo! Finance]
11/10
01:48 pm
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
Low
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
11/10
08:18 am
nrxp
HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health [Yahoo! Finance]
Low
Report
HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health [Yahoo! Finance]
11/10
08:03 am
nrxp
HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
Low
Report
HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
10/30
08:09 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its price target raised by analysts at Ascendiant Capital Markets from $46.00 to $47.00. They now have a "buy" rating on the stock.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its price target raised by analysts at Ascendiant Capital Markets from $46.00 to $47.00. They now have a "buy" rating on the stock.
10/21
08:05 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
10/20
08:03 am
nrxp
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director
Low
Report
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director
10/16
08:08 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
10/6
08:18 am
nrxp
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference [Yahoo! Finance]
Low
Report
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference [Yahoo! Finance]
10/6
08:03 am
nrxp
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference
Low
Report
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference